CymaBay Therapeutic (CBAY) PT Lowered to $15 at Evercore ISI, Following Pharma Study Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
CymaBay Therapeutic (CBAY) Sell-Off 'Overdone' - SunTrust
June 11, 2019 1:25 PM EDTSunTrust analyst Edward Nash reiterated a Buy rating and $19.00 price target on CymaBay Therapeutic (NASDAQ: CBAY), saying the sell-off is overdone.
Nash commented, "Although the lack of effect on liver fat makes seladelpar less attractive, we believe investors should not completely... More
CymaBay Therapeutic (CBAY) PT Lowered to $12 at Oppenheimer
June 11, 2019 12:00 PM EDTOppenheimer analyst Jay Olson lowered the price target on CymaBay Therapeutic (NASDAQ: CBAY) to $12.00 (from $18.00) while maintaining a Outperform rating.
Olson commented, "Seladelpar missed the primary efficacy endpoint of MRI-PDFF at week 12 in a Ph2 NASH study. Seladelpar did achieve significant and dose-dependent... More
